These Analysts Boost Their Forecasts On Glaukos Following Q4 Results

Glaukos Corp (NYSE: GKOS) reported mixed results for the fourth quarter on Tuesday.

Benzinga • Feb 18, 2026

Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook

GKOS posts 36% Q4 revenue jump, raises 2026 sales outlook to $600-$620M as iDose TR and Epioxa fuel growth despite wider loss.

Zacks Investment Research • Feb 18, 2026

Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript

Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 18, 2026

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key highlights include: Record net sales of $143.1 million in Q4 2025 increased 36% year-over-year on a reported basis and 34% year-over-year on a constant currency basis.

Business Wire • Feb 17, 2026

Glaukos (GKOS) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Feb 18, 2026

Glaukos (GKOS) Reports Q4 Loss, Beats Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.4 per share a year ago.

Zacks Investment Research • Feb 17, 2026

Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy?

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 10, 2026

Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards

Class A shares of the Alger Weatherbie Specialized Growth Fund outperformed the Russell 2500 Growth Index during the fourth quarter of 2025. Natera, Inc., ACADIA Pharmaceuticals Inc., and Glaukos Corp were among the top contributors to performance. FirstService Corp, AAR CORP., and Kratos Defense & Security Solutions, Inc. were among the top detractors from performance.

Seeking Alpha • Feb 3, 2026

Director Sells GKOS 15,000 Shares for $1.9 Million

15,000 shares were exercised as options and immediately sold in the open market for a total of ~$1.9 million at around $127.71 per share on Jan. 22, 2026. This transaction represented 28.60% of Stapley's direct holdings, reducing his direct stake from 52,449 to 37,449 shares, with post-trade direct holdings valued at ~$4.7 million.

The Motley Fool • Jan 31, 2026

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

GKOS is positioned for growth as interventional glaucoma adoption expands, iDose and iStent synergies build, and scale drives operating leverage despite margin pressures.

Zacks Investment Research • Jan 29, 2026